Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.88 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 3/20 | 0.35 |
| ▸ | GABRD | O14764 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL10710877 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL3076649 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL2017287 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL229818 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL17113862 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL3486854 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL27597271 | 0.95 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL1813972 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL8516 | 0.94 | — | — | |
| Valine SCHEMBL288203 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | claimed |
| US-20240196946-A1 | METABOLICALLY MODIFIED VANILLA BEANS AND METHODS FOR PRODUCING SAME | VANILLA TECHNOLOGIES LTD. (IL) | 2024-06-20 | — | — | US | claimed |
| EP-4287847-A1 | METABOLICALLY MODIFIED VANILLA BEANS AND METHODS FOR PRODUCING SAME | Vanilla Technologies Ltd. (IL) | 2023-12-13 | — | — | EP | claimed |
| CN-117062541-A | Metabolically modified vanilla beans and method for producing same | 香草技术有限公司 | 2023-11-14 | — | — | CN | claimed |
| EP-3946635-A2 | LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES | ALTIMMUNE UK LIMITED (GB) | 2022-02-09 | — | — | EP | claimed |
| WO-2021151891-A1 | NOVEL PHYTOENE DESATURASE VARIANTS TO PRODUCE NEUROSPORENE AND/OR ZETA-CAROTENE | DEINOVE (FR) | 2021-08-05 | — | — | WO | claimed |
| US-20180104321-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | Autolus Limited (GB) | 2018-04-19 | — | — | US | claimed |
| US-9005575-B2 | Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | STC.UNM (US) | 2015-04-14 | — | — | US | claimed |
| US-20120177722-A1 | Lyaseenzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION | 2012-07-12 | — | — | US | claimed |
| US-7163814-B2 | Modified reductase and its gene, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-16 | — | — | US | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| JP-60083580-A | — | — | None | — | — | JP | disclosed |
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-117903324-B | Pharmaceutical preparation for targeted degradation of hepatitis B virus X protein and application thereof | 珠海市人民医院 | 2024-07-23 | — | — | CN | disclosed |
| US-4959314-A | MUTANTS OF ACTIVE PROTEINS, REPLACING CYSTEINE | CETUS CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| US-4874744-A | TOPICAL APPLICATION | UNIVERSITY OF CINCINNATI (US) | 1989-10-17 | — | — | US | disclosed |
| JP-S6083580-A | METHOD FOR CULTIVATING BACTERIUM OF GENUS PSEUDOMONAS | YAMADA HIDEAKI | 1985-05-11 | — | — | JP | disclosed |
| JP-S0683580-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177722-A1 | Lyaseenzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them | MTR, HMBS, AMPD1 | SLC7A5 935/4885SLC1A3 1561/4885SLC1A2 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.